In an approach to design drugs with higher affinity for π-π stacking and electrostatic interactions with targeted biomolecules, complexes of the type [{cis-Pt(A)2(L)}2-μ-{trans-1,4-dach}](NO3)4 ((A)2 = (NH3)2 or ethylenediamine (en), L = quinoline (quin) or benzothiazole (bztz), dach = trans-1,4-diaminocyclohexane) were synthesized. The quinoline complex, [{cis-Pt(en)(quin)}2-μ-(dach)](NO3)4 (9) was synthesized from the precursor K[PtCl3(quin)] (1) while the benzothiazole complexes, [{cis-Pt(A)2(bztz)}2-μ-(dach)](NO3)4 ((A)2 = (NH3)2 (10); (A)2 = en (11)) were synthesized from the precursors cis-[Pt(A)2Cl(bztz)] ((A)2 = (NH3)2 (7); (A)2 = en (8)). Their interactions with N-acetyltryptophan and a model pentapeptide (N-AcWLASW-OH) modeled on the pentapeptide recognition sequence of p53-mdm2 (FLASW) were examined by fluorescence spectroscopy. The dinuclear complexes were found to be significantly stronger quenchers of fluorescence than their mononuclear Pt analogs. Molecular modeling suggests a “sandwich” mode of binding and the flexibility of the dinculear motif can allow design for more selective and stronger-binding complexes. Based on these results a further prototype, [{Pt(en)(9-EtGua)}2μ-H2N(CH2)6NH2]4+, incorporating the purine 9-Ethylguanine (9-EtG) as a stacking moiety was prepared which showed good cytotoxicity in A2780 and OsACL tumor cell lines.